Another Scandal in Evidence-Based Medicine: Ambulatory BP Monitoring Questioned?

Apparently, the scandal surrounding the EXCEL trial kicked the hornet’s nest as far as evidence-based medicine is concerned. This time, the stars were the actual authors of an article published in the prestigious New England Journal of Medicine (NEJM): the investigators retracted their paper due to issues in data analysis.

Otro “escándalo” en la medicina basada en la evidencia ¿El monitoreo ambulatorio de presión puesto en duda?

The aforementioned work was originally published in 2018 in the most prestigious medical journal worldwide, and it showed that ambulatory blood pressure monitoring readings were strongly associated with mortality. In that sense, the association was stronger than with readings obtained at the doctor’s office.

At the time, the lead author had mentioned that his work was the largest worldwide and provided unequivocal evidence that [ambulatory blood pressure monitoring] is superior to clinic pressure at predicting total and cardiovascular mortality. This week, the authors themselves retracted the article due to problems in statistical analyses.


Read also: Latest Guidelines “Dropped” After Scandal Over EXCEL Results.


Now, an independent statistical team is working with the aim of publishing the results as soon as possible.

The original suspicion was confirmed when researchers attempted to replicate findings in the International Database on Ambulatory Blood Pressure in Relation to Cardiovascular Outcomes.


Read also: Treating Both Atrial Valves Improves Survival.


Despite everything, ambulatory blood pressure monitoring is still the most suitable method to diagnose and manage hypertension.

2020-03-09-banegas2018 2020-03-09-nejmc2001445

Original title: Retraction: Relationship between clinic and ambulatory blood-pressure measurements a. nd mortality.

Reference: Banegas JR et al. N Engl J Med. 2020; Epub ahead of print.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Dual Antiplatelet Therapy in Diabetic Patients with AMI: De-Escalation Strategy

Diabetes Mellitus (DM) is a common comorbidity in patients hospitalized for acute coronary syndrome (ACS) of increasing prevalence over the last decade, associated with...

AHA 2025 | OPTIMA-AF: 1 Month vs. 12 Months of Dual Therapy (DOAC + P2Y12) After PCI in Atrial Fibrillation

Concomitant atrial fibrillation (AF) and coronary artery disease is a common occurrence in clinical practice. In these patients, current guidelines recommend 1 month of...

AHA 2025 | OCEAN Study: Anticoagulation vs. Antiplatelet Therapy After Successful Atrial Fibrillation Ablation

After a successful atrial fibrillation (AF) ablation, the need to maintain long-term anticoagulation (AC) remains uncertain, especially considering the very low residual embolic risk...

AHA 2025 | VESALIUS-CV: Evolocumab in High-Cardiovascular-Risk Patients Without Prior MI or Stroke

LDL cholesterol is a well-established factor for cardiovascular disease. Therapy with PCSK9 inhibitors, including evolocumab, has been shown to reduce the risk of cardiovascular...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Transapical TMVR in High Risk Patients: Intrepid 5-Year Outcomes

Moderate to severe mitral valve regurgitation (MR) continues is still a high prevalence condition with bad prognosis, particularly among the elderly with left ventricular...

EMERALD II: Non-Invasive Coronary Anatomy and Physiology (CCTA) in ACS Prediction

Despite steady progress in secondary prevention and medical treatment optimization (OMT), acute coronary syndrome (ACS) remains one of the leading causes of cardiovascular morbimortality....

Impact of Balloon Post-Dilation on the Long-Term Durability of Bioprostheses after TAVR

Balloon post-dilation (BPD) during transcatheter aortic valve replacement (TAVR) allows for the optimization of prosthesis expansion and the reduction of residual paravalvular aortic regurgitation....